IPERION (IPR) presentation summary

Meeting formalities and voting

• Virtual attendance was open to all interested parties, with the meeting recorded for transparency.

• Voting was conducted electronically, with an option to submit votes via email until 4pm on the meeting day.

Financial review for year ended 31 March 2024

• Interest income increased due to higher bank rates, reaching $41,396 in 2024.

• Outsource plant expense was $500,000, including establishment costs.

• Admin expenses rose, mainly from audit fees, plant oversight, and marketing.

• Impairment expense on trademark intangibles is expected to reverse with future sales.

• Net assets declined to $804,081, with cash and term deposits at $866,481.

Business progress and product development

• Company rebranded and launched marketing at major exhibitions in Dubai, Bangkok, Singapore, and Malaysia.

• Pathoglaze® registered as a trademark in multiple regions and certified as a green technology product.

• Product trials are ongoing with customers in Germany, Japan, Taiwan, and others.

• Cash conservation measures in place, with some plant costs supported by research grants.